+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy



Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy



Clinical Genitourinary Cancer 11(4): 423-430



The modified Glasgow Prognostic Score (mGPS), derived from C-reactive protein (CRP) and albumin levels, and the neutrophil-lymphocyte ratio (NLR) have demonstrated prognostic significance in a number of malignancies. Baseline mGPS and NLR were calculated in a prospective cohort of chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC) (AT-101-CS-205 trial) who received docetaxel and prednisone ± AT101. Cox proportional hazards regression models estimated their effects on overall survival (OS). Of 220 eligible patients, mGPS and neutrophil and lymphocyte counts were available for 184, 193, and 112 patients, respectively. Albumin (hazard ratio [HR], 0.28; 95% confidence interval [CI]: 0.14-0.56; P < .001) and CRP (HR, 1.22; 95% CI, 1.00-1.48; P = .048) were independently prognostic for OS. An association between mGPS and OS was found (HR, 1.87; 95% CI, 1.35-2.59; P < .001; median survival, 23.5 months at mGPS 0 vs. 9.8 months at mGPS 2). mGPS was significant after controlling for 3 previously published nomograms or NLR (P ≤ .001). NLR was not prognostic for OS (HR, 0.98; P = .91), and no association between mGPS and toxicity was noted. Our results demonstrate the prognostic role of the mGPS in mCRPC over variables previously identified. mGPS is inexpensive, easily measured, and could be incorporated into routine clinical testing if our results are confirmed in a subsequent validation study. The utility of the NLR in mCRPC remains uncertain despite evidence in other malignancies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036956800

Download citation: RISBibTeXText

PMID: 23816526

DOI: 10.1016/j.clgc.2013.04.020


Related references

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian Journal of Andrology 15(1): 110-115, 2013

Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. Bju International 110(11 Pt B): E461-E468, 2013

The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy. Journal of ChemoTherapy 27(1): 35-39, 2015

Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel. Hinyokika Kiyo. Acta Urologica Japonica 58(1): 7-11, 2012

P090 Time to prostate specific antigen nadir as a prognostic factor in metastatic castration-resistant prostate cancer under docetaxel. European Urology Suppl.s 13(5): 143-144, 2014

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. Oncotarget 8(33): 55374-55383, 2017

The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. Anticancer Research 35(5): 3075-3079, 2015

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate International 7(1): 9-14, 2019

Mp87-07 Prognostic Factors For Overall Survival In Patients With Castration-Resistant Prostate Cancer Treated By Intermittent Chemotherapy With Docetaxel And Prednisolone. The Journal of Urology 193(4): e1086-e1087, 2015

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology 27(3): 454-460, 2016

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. Bmc Cancer 16: 109, 2016

A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223 Radium-dichloride. Annals of Nuclear Medicine 32(2): 142-148, 2017

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. Bmc Urology 16: 13, 2016

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. Journal of the National Cancer Institute 105(22): 1729-1737, 2014

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Canadian Urological Association Journal 12(2): E47-E52, 2018